Research Summary: Many estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) breast tumors develop resistance to aromatase inhibitors (AIs) alone or in combination with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. However, the capacity for selective ER degraders (SERDs) to induce ER alpha degradation...
Read MoreCOVID-19 infection and impact on cancer recurrence: comprehensive results from over 32,000 patients with breast cancer. In this study, researchers assessed the relationship between COVID-19 infection after breast cancer diagnosis and cancer recurrence. In total, 32,871 patients diagnosed with localized breast cancer from January 1,...
Read MoreReprinted with permission. Ann Med Surg (Lond). 2026;88(4):2610–2615.* by Emmanuel Ifeanyi Obeagu Dr. Obeagu is with Division of Haematology, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, and The Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of...
Read MorePrognostic value of Ki-67 and progesterone receptor for risk stratification and outcomes by adjuvant chemotherapy in early luminal-type breast cancer Chen HH, Chang SJ, Kan JY, et al. Breast Cancer (Dove Med Press). 2026;18:597707. Summary. In this retrospective study, researchers developed a model utilizing progesterone...
Read MoreMolecular Features of Response to Palbociclib + Fulvestrant ± Inavolisib in Hormone Receptor–positive, HER2-negative, PIK3CA-mutated Advanced Breast Cancer as Assessed from Baseline Circulating Tumor DNA in the Pivotal Phase 3 INAVO120 Trial Inavolisib plus palbociclib and fulvestrant is approved for the treatment of PIK3CA-mutated, hormone...
Read MoreLearn how capivasertib plus fulvestrant works in advanced breast cancer, including its effectiveness, safety, and why this dosing approach may help improve treatment outcomes.
Read MoreExplore key breast cancer insights from ESMO 2025, including new treatment data, survival trends, and emerging biomarkers shaping future care decisions.
Read More©2026 Oncology Matrix. All Rights Reserved.
